|
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549 | |||||
|
FORM
8-K | |||||
|
| |||||
|
CURRENT
REPORT PURSUANT | |||||
|
TO
SECTION 13 OR 15(d) | |||||
|
OF
THE SECURITIES EXCHANGE ACT OF 1934 | |||||
|
Date
of Report (Date of earliest event reported): March 29,
2005 | |||||
|
GENEX
PHARMACEUTICAL, INC. | |||||
|
(Exact
name of registrant as specified in its charter) | |||||
|
Delaware |
333-102118 |
98-0383571 | |||
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
| |||
| 1801 Guangyin Building, Youyibeilu, Hexi District, Tianjin City, China 300074 | |||||
|
(Address
of principal executive offices) (Zip
Code) | |||||
|
86-22-233-70440 | |||||
|
(Registrant's
telephone number, including area code) | |||||
|
KS
E-Media Holdings, Inc. | |||||
|
(Former
name, former address and former fiscal year, if changed since last
report) | |||||
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions: | |||||
|
__
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) | |||||
|
__
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) | |||||
|
__
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) | |||||
|
__
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) | |||||
| (a) |
On
March 29, 2005, the Board of Directors of the Registrant dismissed
Weinberg & Company, Inc. as its independent auditors. On March 29,
2005, the Board appointed Kabani & Company to serve as the
Registrant’s independent auditors. None of the reports of Weinberg &
Company, Inc. on the Registrant’s financial statements since the last
fiscal quarter ended September 30, 2004 contained an adverse opinion or a
disclaimer of opinion, nor were they qualified or modified as to
uncertainty, audit scope or accounting principles. From the time Weinberg
& Company, Inc. was engaged as the Registrant’s independent auditors
and during any subsequent interim period preceding the dismissal, there
were no disagreements with Weinberg & Company, Inc. on any matter of
accounting principles or practices, financial statement disclosure, or
auditing scope or procedure which, if not resolved to Weinberg &
Company, Inc.’s satisfaction, would have caused Weinberg & Company,
Inc. to make reference to the subject matter in connection with its report
on the Registrant’s financial statements during such periods; and there
were no reportable events as defined in Item 304(a)(1)(v) of Regulation
S-K. |
| GENEX PHARMACEUTICAL, INC. | ||
| |
|
|
| Date: April 1, 2005 | By: | /s/ Fuzhi Song |
|
Fuzhi Song | ||
| Chief Executive Officer | ||